For instance, in a phase 3 randomized trial, patients with advanced melanoma treated with the gp100 peptide vaccine and interleukin-2 showed a significantly higher overall clinical response rate (16% vs. 6%) and longer PFS (2.2 vs. 1.6 months) compared to those receiving interleukin-2 alone [21]. Here, IL2 is linked to melanoma.